EDIT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EDIT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Editas Medicine's annualized ROCE % for the quarter that ended in Dec. 2024 was -52.91%.
The historical data trend for Editas Medicine's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
ROCE % | Get a 7-Day Free Trial |
![]() |
![]() |
-27.99 | -33.74 | -41.66 | -38.01 | -68.23 |
Editas Medicine Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
ROCE % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-21.73 | -66.18 | -84.05 | -92.86 | -52.91 |
Editas Medicine's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2024 ) | (A: Dec. 2023 ) | (A: Dec. 2024 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2024 ) | (A: Dec. 2023 ) | (A: Dec. 2024 ) | |||||
= | -238.92 | / | ( ( (499.153 - 63.217) | + | (341.589 - 77.225) ) | / 2 ) | |
= | -238.92 | / | ( (435.936 | + | 264.364) | / 2 ) | |
= | -238.92 | / | 350.15 | ||||
= | -68.23 % |
Editas Medicine's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Dec. 2024 ) | (Q: Sep. 2024 ) | (Q: Dec. 2024 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Dec. 2024 ) | (Q: Sep. 2024 ) | (Q: Dec. 2024 ) | |||||
= | -137.444 | / | ( ( (327.567 - 72.353) | + | (341.589 - 77.225) ) | / 2 ) | |
= | -137.444 | / | ( ( 255.214 | + | 264.364 ) | / 2 ) | |
= | -137.444 | / | 259.789 | ||||
= | -52.91 % |
(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (NAS:EDIT) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Editas Medicine's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Baisong Mei | officer: SVP, CHIEF MEDICAL OFFICER | C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142 |
Gilmore Neil O'neill | director, officer: CEO | 215 FIRST STREET, CAMBRIDGE MA 02142 |
Linda Burkly | officer: EVP, CHIEF SCIENTIFIC OFFICER | 1 MAIN STREET, CAMBRIDGE MA 02142 |
Erick Lucera | officer: EVP, CHIEF FINANCIAL OFFICER | 138 THISTLE ROAD, NORTH ANDOVER MA 08145 |
Jessica Hopfield | director | C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
Bruce Eaton | officer: EVP, Chief Business Officer | C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142 |
Michelle Robertson | officer: Chief Financial Officer | C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Elliott M. Levy | director | C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140 |
Mark S Shearman | officer: EVP, Chief Scientific Officer | C/O APPLIED GENETIC TECHNOLOGIES CORP, 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615 |
Lisa Anne Michaels | officer: EVP/Chief Medical Officer | C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142 |
Bernadette Connaughton | director | C/O VISTERRA, INC., ONE KENDALL SQUARE, #B3301, CAMBRIDGE MA 02139 |
James C Mullen | director | 940 WINTER STREET, PERKINELMER, INC LEGAL DEPARTMENT, WALTHAM MA 02451 |
Emma Reeve | director | C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451 |
Cynthia Collins | director | 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878 |
Meeta Chatterjee | director | C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142 |
From GuruFocus
By GuruFocus News • 10-22-2024
By Muslim Farooque • 12-13-2024
By Marketwired • 10-21-2024
By Marketwired • 10-22-2024
By GuruFocus News • 10-10-2024
By GuruFocus News • 10-17-2024
By GuruFocus Research • 08-07-2024
By Marketwired • 12-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.